Cover Image

Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review

Saved in:

Bibliographic Details
Main Authors:	Siddhartha Sood, HBSc (Author), Ahmed Bagit, BSc (Author), Martin Heung (Author), Khalad Maliyar, MD (Author), Abrahim Abduelmula, MD (Author), Muskaan Sachdeva, MD (Author), Jorge R. Georgakopoulos, MD (Author), Asfandyar Mufti, MD (Author), Vimal H. Prajapati, MD (Author), Jensen Yeung, MD (Author)
Format:	Book
Published:	Elsevier, 2024-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

Use of sulfasalazine for psoriasis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022)

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
by: Siddhartha Sood, HBSc, et al.
Published: (2023)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023)

Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review
by: Siddhartha Sood, HBSc, et al.
Published: (2023)

COVID-19 and wound care: A Canadian perspective
by: Asfandyar Mufti, MD, et al.
Published: (2020)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
by: Asfandyar Mufti, MD, et al.
Published: (2021)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literatureCapsule Summary
by: Asfandyar Mufti, MD, et al.
Published: (2021)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
by: Muskaan Sachdeva, BHSc, et al.
Published: (2021)

Immune checkpoint inhibitor induced lichenoid reactions: A systematic review of characteristics and treatment outcomes
by: Abrahim Abduelmula, BScN, et al.
Published: (2022)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022)

Treatment of hypertrophic lichen planus using deucravacitinib
by: Siddhartha Sood, HBSc, et al.
Published: (2024)

Two-year efficacy, safety, and drug survival of dupilumab for atopic dermatitis: A real-world Canadian multicenter retrospective study
by: Jorge R. Georgakopoulos, MD, et al.
Published: (2021)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
by: Yuliya Lytvyn, et al.
Published: (2022)

Vitiligo during dupilumab therapy
by: Vincenzo Picone, MD, et al.
Published: (2023)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
by: Carine M. Lama, MS, et al.
Published: (2023)

Lichenoid-granulomatous drug reactions to dupilumab: A report of 2 cases
by: Zahra Rehan, BSc, et al.
Published: (2023)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023)

Dupilumab-induced pityriasis rosea
by: Morgan Zabel, BS, et al.
Published: (2023)

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo
by: Shanthi Narla, MD, et al.
Published: (2020)

Disparities in Janus kinase inhibitor access for alopecia areata: a retrospective analysis
by: Elizabeth J. Klein, MD, et al.
Published: (2024)

Eczematous liraglutide eruption managed by dupilumab: A case report
by: Claudia Paganini, MD, et al.
Published: (2024)

Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib
by: Jannett Nguyen, MD, et al.
Published: (2021)

Acne keloidalis nuchae in a patient with atopic dermatitis treated with Janus kinase inhibitor upadacitinib
by: Nicolas Caudrelier, MD, et al.
Published: (2023)

Dupilumab-induced erythema nodosum
by: Danielle E. Mustin, MEng, et al.
Published: (2022)

Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid
by: William Damsky, MD, PhD, et al.
Published: (2020)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
by: Yuliya Lytvyn, PhD, et al.
Published: (2021)

Pyoderma gangrenosum developing in a patient treated with dupilumab
by: Jessica Nasseh, MD, et al.
Published: (2022)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
by: Maria Esposito, MD, et al.
Published: (2023)

Novel use of dupilumab in pemphigus vulgaris and pemphigus foliaceus
by: Christina Jiang, BS, MS, et al.
Published: (2023)

A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor
by: Yuta Koike, MD, PhD, et al.
Published: (2017)

A novel application of dupilumab in treatment-resistant follicular mucinosis
by: Saud Binsufayan, MD, et al.
Published: (2023)

Angioimmunoblastic T-cell lymphoma unmasked by treatment with dupilumab
by: Zi-Yi Choo, BS, et al.
Published: (2023)

Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab
by: Leah Laageide, MD, et al.
Published: (2021)

Dupilumab, incontinentia pigmenti, and alopecia: A serendipitous observation
by: Ashley Torkan Zilberstein, MD, et al.
Published: (2022)

Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
by: Yassaman Alipour Tehrany, MD, et al.
Published: (2021)

Assessing the use of dupilumab in a pediatric patient with bullous congenital ichthyosiform erythroderma
by: Nouf Almuhanna, MD, et al.
Published: (2023)